FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Martin Oken

Research Profile

Disorders

Procedures

Concepts & Ideas

Chemicals & Drugs

Anatomy

Co-author Network

Publications

TOP 3
Martin M Oken; Paul F Pinsky; Philip C Prorok; Lawrence R Ragard; Joshua M Rathmell; Douglas J Reding; Thomas L Riley; Joel L Weissfeld; Patrick Wright; Lance A Yokochi; Gerald L Andriole; Christine D Berg; Saundra S Buys; Neil Caparaso; Timothy R Church; E David Crawford; Mona N Fouad; John K Gohagan; Willam G Hocking; Ping Hu; Claudine Isaacs; Grant Izmirlian; Barnett S Kramer; Paul A Kvale; Anthony B Miller; Barbara O'Brien
Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial.
Angela Dispenzieri; Lijun Zhang; Jerry A Katzmann; Melissa Snyder; Emily Blood; Roberta Degoey; Kim Henderson; Robert A Kyle; Martin M Oken; Arthur R Bradwell; Philip R Greipp
Appraisal of immunoglobulin free light chain as a marker of response.
Wee J Chng; Tammy Price-Troska; N Gonzalez-Paz; Scott A Van Wier; S Jacobus; Emily Blood; K Henderson; Martin M Oken; Brian Van Ness; Philip R Greipp; S Vincent Rajkumar; Rafael Fonseca
Clinical significance of TP53 mutation in myeloma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Martin Oken (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Martin M Oken; Paul F Pinsky; Philip C Prorok; Lawrence R Ragard; Joshua M Rathmell; Douglas J Reding; Thomas L Riley; Joel L Weissfeld; Patrick Wright; Lance A Yokochi; Gerald L Andriole; Christine D Berg; Saundra S Buys; Neil Caparaso; Timothy R Church; E David Crawford; Mona N Fouad; John K Gohagan; Willam G Hocking; Ping Hu; Claudine Isaacs; Grant Izmirlian; Barnett S Kramer; Paul A Kvale; Anthony B Miller; Barbara O'Brien
Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial.
JAMA : the journal of the American Medical Association 2011;306(17):1865-73.
2008: Angela Dispenzieri; Lijun Zhang; Jerry A Katzmann; Melissa Snyder; Emily Blood; Roberta Degoey; Kim Henderson; Robert A Kyle; Martin M Oken; Arthur R Bradwell; Philip R Greipp
Appraisal of immunoglobulin free light chain as a marker of response.
Blood 2008;111(10):4908-15.
2007: Wee J Chng; Tammy Price-Troska; N Gonzalez-Paz; Scott A Van Wier; S Jacobus; Emily Blood; K Henderson; Martin M Oken; Brian Van Ness; Philip R Greipp; S Vincent Rajkumar; Rafael Fonseca
Clinical significance of TP53 mutation in myeloma.
Leukemia 2007;21(3):582-4.
2007: Natalia Gonzalez-Paz; Wee J Chng; Rebecca F McClure; Emily Blood; Martin M Oken; Brian Van Ness; C David James; Paul J Kurtin; Kim Henderson; Gregory J Ahmann; Morie A Gertz; Martha Lacy; Angela Dispenzieri; Philip R Greipp; Rafael Fonseca
Tumor suppressor p16 methylation in multiple myeloma: biological and clinical implications.
Blood 2007;109(3):1228-32.
2006: Robert A Kyle; Traci Leong; Shuli Li; Martin M Oken; Neil E Kay; Brian Van Ness; Philip R Greipp
Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation.
Cancer 2006;106(9):1958-66.
2006: Wee J Chng; Rafael Santana-Dávila; Scott A Van Wier; Gregory J Ahmann; Syed M Jalal; P Leif Bergsagel; Marta Chesi; Mike C Trendle; S Jacobus; Emily Blood; Martin M Oken; K Henderson; Robert A Kyle; Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Philip R Greipp; Rafael Fonseca
Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations.
Leukemia 2006;20(5):807-13.
2006: Wee J Chng; Jerry M Winkler; Philip R Greipp; Syed M Jalal; P Leif Bergsagel; Marta Chesi; Mike C Trendle; Gregory J Ahmann; Kim Henderson; Emily Blood; Martin M Oken; A Hulbert; Scott A Van Wier; Rafael Santana-Dávila; Robert A Kyle; Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Rafael Fonseca
Ploidy status rarely changes in myeloma patients at disease progression.
Leukemia research 2006;30(3):266-71.
2005: Wee J Chng; Scott A Van Wier; Gregory J Ahmann; Jerry M Winkler; Syed M Jalal; P Leif Bergsagel; Marta Chesi; Mike C Trendle; Martin M Oken; Emily Blood; Kim Henderson; Rafael Santana-Dávila; Robert A Kyle; Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Philip R Greipp; Rafael Fonseca
A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS.
Blood 2005;106(6):2156-61.
2004: Martin M Oken; Sandra Lee; Neil E Kay; William Knospe; Peter A Cassileth
Pentostatin, chlorambucil and prednisone therapy for B-chronic lymphocytic leukemia: a phase I/II study by the Eastern Cooperative Oncology Group study E1488.
Leukemia & lymphoma 2004;45(1):79-84.
2003: Rafael Fonseca; Carina S Debes-Marun; Elisa Beth Picken; Gordon W Dewald; Sandra C Bryant; Jerry M Winkler; Emily Blood; Martin M Oken; Rafael Santana-Dávila; Natalia González-Paz; Robert A Kyle; Morie A Gertz; Angela Dispenzieri; Martha Q Lacy; Philip R Greipp
The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma.
Blood 2003;102(7):2562-7.
2003: Peter H Wiernik; Peter A Cassileth; Traci Leong; H Clark Hoagland; John M Bennett; Elisabeth Paietta; Martin M Oken
A randomized trial of induction therapy (daunorubicin, vincristine, prednisone versus daunorubicin, vincristine, prednisone, cytarabine and 6-thioguanine) in adult acute lymphoblastic leukemia with long-term follow-up: an Eastern Cooperative Oncology Group Study (E3486).
Leukemia & lymphoma 2003;44(9):1515-21.
2003: Rafael Fonseca; Emily Blood; Montserrat Rue; David Harrington; Martin M Oken; Robert A Kyle; Gordon W Dewald; Brian Van Ness; Scott A Van Wier; Kimberly J Henderson; Richard J Bailey; Philip R Greipp
Clinical and biologic implications of recurrent genomic aberrations in myeloma.
Blood 2003;101(11):4569-75.
2002: Anthony Calabro; Martin M Oken; Vincent C Hascall; Anna M Masellis
Characterization of hyaluronan synthase expression and hyaluronan synthesis in bone marrow mesenchymal progenitor cells: predominant expression of HAS1 mRNA and up-regulated hyaluronan synthesis in bone marrow cells derived from multiple myeloma patients.
Blood 2002;100(7):2578-85.
2002: Rafael Fonseca; Emily Blood; Martin M Oken; Robert A Kyle; Gordon W Dewald; Richard J Bailey; Scott A Van Wier; Kimberly J Henderson; James D Hoyer; David Harrington; Neil E Kay; Brian Van Ness; Philip R Greipp
Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients.
Blood 2002;99(10):3735-41.
2002: Rafael Fonseca; David Harrington; Martin M Oken; Gordon W Dewald; Richard J Bailey; Scott A Van Wier; Kimberly J Henderson; Emily Blood; S Vincent Rajkumar; Neil E Kay; Brian Van Ness; Philip R Greipp
Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study.
Cancer research 2002;62(3):715-20.
2001: Neil E Kay; TL Leong; Nancy D Bone; D H Vesole; Philip R Greipp; Brian Van Ness; Martin M Oken; R A Kyle
Blood levels of immune cells predict survival in myeloma patients: results of an Eastern Cooperative Oncology Group phase 3 trial for newly diagnosed multiple myeloma patients.
Blood 2001;98(1):23-8.
2001: Rafael Fonseca; Martin M Oken; David Harrington; Richard J Bailey; Scott A Van Wier; Kimberly J Henderson; Neil E Kay; Brian Van Ness; Philip R Greipp; Gordon W Dewald
Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy.
Leukemia 2001;15(6):981-6.
2001: S R Wallace; Martin M Oken; Kathryn L Lunetta; A Panoskaltsis-Mortari; A M Masellis
Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients.
Cancer 2001;91(7):1219-30.
2001: Peter H Wiernik; T Leong; Martin M Oken; R S Neiman; T M Habermann; J M Bennett; S Schuster; J H Glick
Bleomycin, lomustine, cyclophosphamide, vincristine, procarbazine and prednisone (BLEO-CCVPP) in patients with Hodgkin's disease who relapsed after radiotherapy alone: a long-term follow-up study of the Eastern Cooperative Oncology Group (E3481).
Leukemia & lymphoma 2001;40(3-4):357-63.
2001: Bruce Giantonio; Howard Hochster; Ronald Blum; P H Wiernik; Gary R Hudes; J Kirkwood; D Trump; Martin M Oken
Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology Group.
Investigational new drugs 2001;19(1):89-92.
2000: Martin S Tallman; Donna Neuberg; John M Bennett; C J Francois; Elisabeth Paietta; Peter H Wiernik; Gordon Dewald; Peter A Cassileth; Martin M Oken; Jacob M Rowe
Acute megakaryocytic leukemia: the Eastern Cooperative Oncology Group experience.
Blood 2000;96(7):2405-11.
2000: C Robles; K M Kim; Martin M Oken; John M Bennett; L Letendre; Peter H Wiernik; M J O'Connell; Peter A Cassileth
Low-dose cytarabine maintenance therapy vs observation after remission induction in advanced acute myeloid leukemia: an Eastern Cooperative Oncology Group Trial (E5483).
Leukemia 2000;14(8):1349-53.
2000: S Lee; Martin S Tallman; Martin M Oken; Peter A Cassileth; John M Bennett; Peter H Wiernik; Jacob M Rowe
Duration of second complete remission compared with first complete remission in patients with acute myeloid leukemia. Eastern Cooperative Oncology Group.
Leukemia 2000;14(8):1345-8.
2000: Rafael Fonseca; Mike C Trendle; Traci Leong; Robert A Kyle; Martin M Oken; Neil E Kay; Brian Van Ness; Philip R Greipp
Prognostic value of serum markers of bone metabolism in untreated multiple myeloma patients.
British journal of haematology 2000;109(1):24-9.
2000: Howard Hochster; Martin M Oken; Jane N Winter; Leo I Gordon; B G Raphael; John M Bennett; Peter A Cassileth
Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and and long-term follow-up--a report from the Eastern Cooperative Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(5):987-94.
1999: P H Wiernik; Leo I Gordon; Martin M Oken; J E Harris; M J O'Connell
Evaluation of mitoguazone in patients with refractory chronic lymphocytic leukemia: a phase II study (P-H482) of the Eastern Cooperative Oncology Group.
Leukemia & lymphoma 1999;35(3-4):375-7.
1999: Martin M Oken; Traci Leong; R E Lenhard; Philip R Greipp; Neil E Kay; Brian Van Ness; R M Keimowitz; R A Kyle
The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
Cancer 1999;86(6):957-68.
1999: Philip R Greipp; Mike C Trendle; Traci Leong; Martin M Oken; Neil E Kay; Brian Van Ness; Robert A Kyle
Is flow cytometric DNA content hypodiploidy prognostic in multiple myeloma?
Leukemia & lymphoma 1999;35(1-2):83-9.
1999: Mike C Trendle; TL Leong; Robert A Kyle; J A Katzmann; Martin M Oken; Neil E Kay; Brian Van Ness; Philip R Greipp
Prognostic significance of the S-phase fraction of light-chain-restricted cytoplasmic immunoglobulin (cIg) positive plasma cells in patients with newly diagnosed multiple myeloma enrolled on Eastern Cooperative Oncology Group treatment trial E9486.
American journal of hematology 1999;61(4):232-7.
1999: N Kay; Traci Leong; R A Kyle; Philip R Greipp; Brian Van Ness; Nancy D Bone; Martin M Oken
Altered T cell repertoire usage in CD4 and CD8 subsets of multiple myeloma patients, a Study of the Eastern Cooperative Oncology Group (E9487).
Leukemia & lymphoma 1999;33(1-2):127-33.
1999: P Liu; Martin M Oken; Brian Van Ness
Interferon-alpha protects myeloma cell lines from dexamethasone-induced apoptosis.
Leukemia 1999;13(3):473-80.
1999: Howard Hochster; M H Strawderman; J E Harris; Michael B Atkins; Martin M Oken; R T Skeel; S J Jubelirer; D Parkinson
Conventional dose melphalan is inactive in metastatic melanoma: results of an Eastern Cooperative Oncology Group Study (E1687).
Anti-cancer drugs 1999;10(2):245-8.
1998: Peter H Wiernik; V Phillips; F J Camacho; Martin M Oken; M J O'Connell
Methylguazone, vindesine and cisplatin for the treatment of patients with relapsed or refractory malignant lymphoma: an Eastern Cooperative Oncology Group Study (PA482).
Leukemia & lymphoma 1998;30(5-6):619-24.
1998: Peter H Wiernik; D F Moore; J M Bennett; S E Vogl; J E Harris; S Luger; Martin M Oken; J H Glick
Phase II study of mitoguazone, cyclophosphamide, doxorubicin, vincristine and prednisone for patients with diffuse histologic subtypes of non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Study (PE481).
Leukemia & lymphoma 1998;30(5-6):601-7.
1998: Philip R Greipp; TL Leong; J M Bennett; Philippe Gaillard; B Klein; James A Stewart; Martin M Oken; Neil E Kay; Brian Van Ness; Robert A Kyle
Plasmablastic morphology--an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group.
Blood 1998;91(7):2501-7.
1998: Neil E Kay; Traci Leong; Nancy D Bone; R A Kyle; Philip R Greipp; Brian Van Ness; Martin M Oken
T-helper phenotypes in the blood of myeloma patients on ECOG phase III trials E9486/E3A93.
British journal of haematology 1998;100(3):459-63.
1998: Jane N Winter; J Andersen; J C Reed; S Krajewski; Daina Variakojis; K D Bauer; Richard I Fisher; Leo I Gordon; Martin M Oken; S Jiang; D Jeffries; P Domer
BCL-2 expression correlates with lower proliferative activity in the intermediate- and high-grade non-Hodgkin's lymphomas: an Eastern Cooperative Oncology Group and Southwest Oncology Group cooperative laboratory study.
Blood 1998;91(4):1391-8.
1998: John Glick; M L Young; D Harrington; R L Schilsky; T Beck; R Neiman; Richard I Fisher; Bruce A Peterson; Martin M Oken
MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(1):19-26.
1997: Neil E Kay; TL Leong; R A Kyle; Philip R Greipp; Daniel D Billadeau; Brian Van Ness; Nancy D Bone; Martin M Oken
Circulating blood B cells in multiple myeloma: analysis and relationship to circulating clonal cells and clinical parameters in a cohort of patients entered on the Eastern Cooperative Oncology Group phase III E9486 clinical trial.
Blood 1997;90(1):340-5.
1997: Martin M Oken; David Harrington; N Abramson; R A Kyle; W Knospe; J H Glick
Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Cancer 1997;79(8):1561-7.
1997: Martin M Oken
Multiple myeloma: prognosis and standard treatment.
Cancer investigation 1997;15(1):57-64.
1996: P Liu; T Leong; L Quam; Daniel D Billadeau; Neil E Kay; Philip R Greipp; Robert A Kyle; Martin M Oken; Brian Van Ness
Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial.
Blood 1996;88(7):2699-706.
1996: Martin M Oken; Robert A Kyle; Philip R Greipp; Neil E Kay; A Tsiatis; S A Gregory; J Spiegel R; J O'Connell M
Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma.
Leukemia & lymphoma 1996;20(5-6):447-52.
1995: Neil E Kay; Martin M Oken; Nancy D Bone; Robert A Kyle; Philip R Greipp; Brian Van Ness; T Leong
Circulating CD19+ blood cell levels in myeloma. ECOG Myeloma Clinical Trials Laboratory Study Group.
Blood 1995;86(10):4000-1.
1995: Neil E Kay; Martin M Oken; Robert A Kyle; Brian Van Ness; L Kalish; T Leong; Philip R Greipp
Sequential phenotyping of myeloma patients on chemotherapy: persistence of activated T-cells and natural killer cells.
Leukemia & lymphoma 1995;16(3-4):351-4.
1992: Daniel D Billadeau; L Quam; W Thomas; N Kay; Philip R Greipp; Robert A Kyle; Martin M Oken; Brian Van Ness
Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients.
Blood 1992;80(7):1818-24.
1992: Martin M Oken
New agents for the treatment of multiple myeloma and non-Hodgkin lymphoma.
Cancer 1992;70(4 Suppl):946-8.
1991: Daniel D Billadeau; M Blackstadt; Philip R Greipp; Robert A Kyle; Martin M Oken; N Kay; Brian Van Ness
Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction: a technique for sequential quantitation of residual disease.
Blood 1991;78(11):3021-9.
1991: Martin M Oken; Robert A Kyle
Strategies for combining interferon with chemotherapy for the treatment of multiple myeloma.
Seminars in oncology 1991;18(5 Suppl 7):30-2.